{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:55:38Z","timestamp":1793307338448,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"F Hoffmann-La Roche AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.annonc.2026.01.013","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T14:41:19Z","timestamp":1778078479000},"page":"837-848","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["A chemotherapy-free, pathological response-adapted strategy using trastuzumab\u2013pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study"],"prefix":"10.1016","volume":"37","author":[{"given":"L.","family":"Garrig\u00f3s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1181-5622","authenticated-orcid":false,"given":"M.","family":"Ruiz-Borrego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"P\u00e9rez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0318-9120","authenticated-orcid":false,"given":"A.","family":"Guerrero-Zotano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3006-7583","authenticated-orcid":false,"given":"A.","family":"Cort\u00e9s-Salgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kuemmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5743-3013","authenticated-orcid":false,"given":"M.","family":"Colleoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Reboredo-Rendo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7773-5994","authenticated-orcid":false,"given":"B.","family":"Bermejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5867-6615","authenticated-orcid":false,"given":"I.","family":"Blancas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Gavila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2307-8869","authenticated-orcid":false,"given":"A.","family":"Stradella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Cara\u00f1ana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Mart\u00ednez-de Due\u00f1as","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4144-3348","authenticated-orcid":false,"given":"C.","family":"Albacar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Ballesteros-Cidras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Martrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Iacobucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Boix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Berenguer-Molins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Alcal\u00e1-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7623-1583","authenticated-orcid":false,"given":"J.","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Llombart-Cussac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Garrig\u00f3s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ruiz-Borrego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"P\u00e9rez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1.","family":"Guerrero-Zotano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cort\u00e9s-Salgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"K\u00fcmmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Colleoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Reboredo-Rendo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Bermejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Blancas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Gavila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Stradella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Cara\u00f1ana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Mart\u00ednez-de Due\u00f1as","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Albacar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Escriv\u00e1-de-Roman\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Musolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Galve-Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Quiroga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Gluz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"L\u00f3pez Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ponce-Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cazzaniga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Cortez-Castedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Sanchez-Rovira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Zamagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Iranzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Collov\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Santaballa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Cavanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bassam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.\u00c1.","family":"Garc\u00eda-S\u00e1enz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Palka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Al-Farhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Ballesteros-Cidras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Martrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Iacobucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Boix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Berenguer-Molins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Alcal\u00e1-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Llombart-Cussac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.annonc.2026.01.013_bib1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab \u2014 mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.annonc.2026.01.013_bib2","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1200\/JCO.2016.71.9815","volume":"35","author":"Harbeck","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.01.013_bib3","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1406281","article-title":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer","volume":"372","author":"Tolaney","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.annonc.2026.01.013_bib4","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer","volume":"377","author":"von Minckwitz","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.annonc.2026.01.013_bib5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2026.01.013_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.2255","article-title":"LBA17 Survival outcome of neoadjuvant endocrine therapy + trastuzumab and pertuzumab (ET+T+P) vs. de-escalated chemotherapy (CT)+T+P in hormone receptor positive (HR+)\/HER2+ early breast cancer (EBC): WSG-TP-II trial","volume":"35","author":"Gluz","year":"2024","journal-title":"Ann Oncol"},{"issue":"9938","key":"10.1016\/j.annonc.2026.01.013_bib7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.annonc.2026.01.013_bib8","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/S1470-2045(21)00122-4","article-title":"Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial","volume":"22","author":"P\u00e9rez-Garc\u00eda","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10437","key":"10.1016\/j.annonc.2026.01.013_bib9","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/S0140-6736(24)00054-0","article-title":"3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial","volume":"403","author":"P\u00e9rez-Garc\u00eda","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2026.01.013_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104751","article-title":"197P Clinical outcomes in patients (pts) with stage cT1\/T2cN0 HER2[+] breast cancer (BC) treated with neoadjuvant trastuzumab and pertuzumab (HP): an exploratory analysis from the PHERGain trial","volume":"10","author":"Garcia","year":"2025","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.annonc.2026.01.013_bib11","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.annonc.2026.01.013_bib12","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1056\/NEJMoa2406070","article-title":"Survival with trastuzumab emtansine in residual HER2-positive breast cancer","volume":"392","author":"Geyer","year":"2025","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.annonc.2026.01.013_bib13","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2026.01.013_bib14","doi-asserted-by":"crossref","first-page":"545","DOI":"10.5858\/arpa.2019-0904-SA","article-title":"Estrogen and progesterone receptor testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Guideline update","volume":"144","author":"Allison","year":"2020","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"10.1016\/j.annonc.2026.01.013_bib15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2026.01.013_bib16","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0","year":"2017"},{"issue":"2","key":"10.1016\/j.annonc.2026.01.013_bib17","first-page":"93","article-title":"The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"24","key":"10.1016\/j.annonc.2026.01.013_bib18","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1200\/JCO.20.03613","article-title":"Updated standardized definitions for efficacy end points (STEEP) in adjuvant breast cancer clinical trials: STEEP version 2.0","volume":"39","author":"Tolaney","year":"2021","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.annonc.2026.01.013_bib19","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1200\/JCO.20.03398","article-title":"Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): a randomized clinical trial","volume":"39","author":"Tolaney","year":"2021","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.annonc.2026.01.013_bib20","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1001\/jamaoncol.2023.0646","article-title":"Efficacy of endocrine therapy plus trastuzumab and pertuzumab vs de-escalated chemotherapy in patients with hormone receptor-positive\/ERBB2 -positive early breast cancer: the neoadjuvant WSG-TP-II randomized clinical trial","volume":"9","author":"Gluz","year":"2023","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.01.013_bib21","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(18)30001-9","article-title":"Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study","volume":"19","author":"Gianni","year":"2018","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2026.01.013_bib22","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.01.013_bib23","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10549-020-05866-1","article-title":"Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study)","volume":"184","author":"Gonz\u00e1lez-Santiago","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"10.1016\/j.annonc.2026.01.013_bib24","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/annonc\/mdx494","volume":"28","author":"Nitz","year":"2017","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2026.01.013_bib26","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(24)00104-9","article-title":"MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study","volume":"25","author":"Van Der Voort","year":"2024","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.01.013_bib27","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.annonc.2025.10.019","article-title":"Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial","volume":"37","author":"Harbeck","year":"2026","journal-title":"Ann Oncol"},{"issue":"suppl 2","key":"10.1016\/j.annonc.2026.01.013_bib28","doi-asserted-by":"crossref","first-page":"S1556","DOI":"10.1016\/j.annonc.2025.09.021","volume":"36","author":"Geyer","year":"2025","journal-title":"Ann Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426000402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426000402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T01:29:02Z","timestamp":1779413342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753426000402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0923753426000402"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2026.01.013","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A chemotherapy-free, pathological response-adapted strategy using trastuzumab\u2013pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}